Thomas Parigger

Investigating T cell abnormalities and its impact on anti-tumor immune responses and clonal evolution with the ultimate goal of improving immune therapy treatment options and to deepen our understanding of immune editing strategies in CLL. Methodologically, I am strongly focusing on various NGS approaches (WES, focused enrichment Seq, amplicon Seq, RNA-Seq, cfDNA Seq and single-cell Seq) as well as on flow cytometric (including CyTOF) analysis.

Responsible for all sales actions as well as all account management activities in my designated area (Western Austria) for the entire Biomarker product portfolio of Thermo Fisher Scientific / BRAHMS measurable on central lab systems or Point-of-Care devices. Besides presenting new products and scientifically discussing product related publications I am accountable for triggering scientific collaborations, organizing scientific trainings and the identification of ongoing market trends.

Master thesis: The Role of Casein Kinases in the Regulation of Oncogenic Hedgehog (Hh) Signaling Cell culture-based analysis of pathway activation after genetic knockdown or chemical perturbation of Hh pathway components. Methods: pPCR, western blot, lentiviral transduction and soft agar assays